Rockwell Medical Beheer

Beheer criteriumcontroles 2/4

De CEO Rockwell Medical is Mark Strobeck, benoemd in Jul2022, heeft een ambtstermijn van 2.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.05M, bestaande uit 53.7% salaris en 46.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.063% van de aandelen van het bedrijf, ter waarde $ 86.24K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.2 jaar en 4.4 jaar.

Belangrijke informatie

Mark Strobeck

Algemeen directeur

US$1.1m

Totale compensatie

Percentage CEO-salaris	53.7%
Dienstverband CEO	2.3yrs
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	2.2yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

The Market Lifts Rockwell Medical, Inc. (NASDAQ:RMTI) Shares 28% But It Can Do More

Sep 29

Rockwell Medical: The Turnaround Is Looking Real

Sep 15

Rockwell Medical, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Aug 11

An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued

Sep 02

Rockwell Medical Q2 Earnings Preview

Aug 12

Rockwell Medical: Triferic Remains Key Despite Sluggish Growth Profile

Mar 02

Rockwell Medical: Down But By No Means Out

Oct 05

Rockwell Medical pops 6% on licensing deal for Triferic AVNU in Turkey

Jun 08

Health Check: How Prudently Does Rockwell Medical (NASDAQ:RMTI) Use Debt?

Mar 08

Some Rockwell Medical, Inc. (NASDAQ:RMTI) Analysts Just Made A Major Cut To Next Year's Estimates

Feb 10

Analyse CEO-vergoeding

Hoe is Mark Strobeck's beloning veranderd ten opzichte van Rockwell Medical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$5m
Mar 31 2024	n/a	n/a	-US$9m
Dec 31 2023	US$1m	US$566k	-US$9m
Sep 30 2023	n/a	n/a	-US$9m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$13m
Dec 31 2022	US$978k	US$267k	-US$19m

Compensatie versus markt: De totale vergoeding ($USD 1.05M ) Mark } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 648.89K ).

Compensatie versus inkomsten: De vergoeding van Mark is gestegen terwijl het bedrijf verliesgevend is.

CEO

Mark Strobeck (53 yo)

2.3yrs

Tenure

US$1,054,169

Compensatie

Dr. Mark Strobeck, Ph D., serves as Independent Director at Windtree Therapeutics, Inc. since June 2023 and is its Lead Independent Director since August 13, 2024. He has served as the President, Chief Exe...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Strobeck	President	2.3yrs	US$1.05m	0.063% $ 86.2k
Jesse Neri	Senior Vice President of Finance	1.1yrs	US$453.18k	geen gegevens
Megan Timmins	Executive VP	3.3yrs	US$660.29k	0.036% $ 49.3k
Timothy Chole	Senior VP & Chief Commercial Officer	less than a year	geen gegevens	0.029% $ 39.9k
Heather Hunter	Senior VP & Chief Corporate Affairs Officer	2.2yrs	geen gegevens	geen gegevens

2.2yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van RMTI wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Mark Strobeck	President	2.3yrs	US$1.05m	0.063% $ 86.2k
John Cooper	Independent Director	7.2yrs	US$142.27k	0.11% $ 153.4k
Robert Radie	Independent Chairman	4.7yrs	US$170.00k	0.11% $ 144.9k
Allen Nissenson	Independent Director	4.4yrs	US$127.94k	0.10% $ 140.7k
Joan Lau	Independent Director	1.1yrs	US$89.51k	0.0065% $ 8.9k
Mark Ravich	Independent Director	7.4yrs	US$128.29k	0.23% $ 311.3k
Andrea Smiley	Independent Director	3.9yrs	US$130.56k	0.10% $ 138.4k

4.4yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van RMTI wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Rockwell Medical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Rockwell Medical, Inc. Promotes Tim Chole to Chief Commercial Officer

Rockwell Medical, Inc., Annual General Meeting, May 21, 2024

Rockwell Medical, Inc. Appoints Jesse Neri as Senior Vice President, Finance

Rockwell Medical, Inc. Appoints Joan Lau, Ph.D. to the Company's Board of Directors

Rockwell Medical, Inc. Announces Resignation of as Senior Vice President, Finance and Chief Accounting Officer

Rockwell Medical, Inc. Names Heather Hunter as SVP, Chief Corporate Affairs Officer

Recent updates

Rockwell Medical, Inc. to Report Q3, 2024 Results on Nov 11, 2024

The Market Lifts Rockwell Medical, Inc. (NASDAQ:RMTI) Shares 28% But It Can Do More

Rockwell Medical: The Turnaround Is Looking Real

New minor risk - Share price stability

Rockwell Medical, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical, Inc. Provides Sales Guidance for the Year 2025 and Beyond

Rockwell Medical, Inc. Launches Convenience Pack to Support Home Hemodialysis and Acute Dialysis Facilities

Rockwell Medical, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Rockwell Medical, Inc.'s (NASDAQ:RMTI) Subdued P/S Might Signal An Opportunity

New major risk - Financial position

Rockwell Medical, Inc. Promotes Tim Chole to Chief Commercial Officer

Consensus EPS estimates fall by 35%, revenue upgraded

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Rockwell Medical, Inc. Revises Earnings Guidance for the Year 2024

Does Rockwell Medical (NASDAQ:RMTI) Have A Healthy Balance Sheet?

Rockwell Medical, Inc. to Report Q1, 2024 Results on May 14, 2024

Rockwell Medical, Inc., Annual General Meeting, May 21, 2024

Consensus EPS estimates upgraded to US$0.10 loss, revenue downgraded

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations

Rockwell Medical, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Is Rockwell Medical (NASDAQ:RMTI) A Risky Investment?

Rockwell Medical, Inc. Provides Earnings Guidance for Fourth Quarter and Full-Year 2023

Rockwell Medical, Inc. (NASDAQ:RMTI) Doing What It Can To Lift Shares

New major risk - Financial position

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical, Inc. Provides Financial Guidance for the Year 2023

Rockwell Medical, Inc. Appoints Jesse Neri as Senior Vice President, Finance

Rockwell Medical, Inc. Appoints Joan Lau, Ph.D. to the Company's Board of Directors

Rockwell Medical, Inc. to Report Q3, 2023 Results on Nov 14, 2023

Is Rockwell Medical (NASDAQ:RMTI) Using Too Much Debt?

Forecast to breakeven in 2025

Rockwell Medical, Inc. Announces Resignation of as Senior Vice President, Finance and Chief Accounting Officer

Consensus EPS estimates fall by 23%

Rockwell Medical, Inc. Revises Financial Guidance for the Year 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Consensus estimates of losses per share improve by 15%

Rockwell Medical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Rockwell Medical, Inc. (NasdaqCM:RMTI) agreed to acquire Substantially All Assets of Evoqua Water Technologies LLC for $16 million.

New major risk - Share price stability

Is Rockwell Medical (NASDAQ:RMTI) Weighed On By Its Debt Load?

Consensus estimates of losses per share improve by 13%

Rockwell Medical, Inc. Provides Revenue Guidance for Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical, Inc. to Report Q4, 2022 Results on Mar 30, 2023

Price target decreased to US$5.00

Rockwell Medical, Inc. Provides Earnings Guidance for the Full Year 2022

Is There Now An Opportunity In Rockwell Medical, Inc. (NASDAQ:RMTI)?

Rockwell Medical, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Rockwell Medical, Inc. Names Heather Hunter as SVP, Chief Corporate Affairs Officer

An Intrinsic Calculation For Rockwell Medical, Inc. (NASDAQ:RMTI) Suggests It's 46% Undervalued

Consensus estimates of losses per share improve by 24%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Rockwell Medical Q2 Earnings Preview

Rockwell Medical, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Price target decreased to US$19.00

Rockwell Medical, Inc. Provides Clinical Update

Rockwell Medical, Inc. announced that it has received $14.9 million in funding

Rockwell Medical Regains Compliance with Nasdaq Listing Requirements

Rockwell Medical, Inc. Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial

Rockwell Medical, Inc. to Report Q1, 2022 Results on May 16, 2022

Rockwell Medical, Inc. Announces Completion of Patient Enrollment Ahead of Schedule in Pivotal Phase 3 Clinical Trial of Triferic(R) in China

Rockwell Medical, Inc. announced delayed annual 10-K filing

Rockwell Medical: Triferic Remains Key Despite Sluggish Growth Profile

Forecast to breakeven in 2023

Price target decreased to US$4.00

Rockwell Medical Receives Important Feedback from FDA on Its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion